| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/12/2009 | WO2009018623A1 Molecular markers and methods related thereto |
| 02/12/2009 | WO2009009739A3 Methods and compositions for facilitating cell death of cancer stem cells and for treating cancer |
| 02/12/2009 | WO2008156614A3 Imidazopyrazines as protein kinase inhibitors |
| 02/12/2009 | WO2008155594A3 Phthalimide derivatives that influence cellular vesicular systems, pharmaceutical compositions, and use thereof |
| 02/12/2009 | WO2008155421A3 Indolin-2-ones and aza-indolin-2-ones |
| 02/12/2009 | WO2008145338A3 Monoclonal antibodies against claudin-18 for treatment of cancer |
| 02/12/2009 | WO2008116129A3 Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
| 02/12/2009 | WO2008113770A3 Anti-androgen peptides and uses thereof in cancer therapy |
| 02/12/2009 | WO2008109454A4 Nucleic acid compounds for inhibiting fos gene expression and uses thereof |
| 02/12/2009 | WO2008087643A3 Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors |
| 02/12/2009 | WO2008086330A3 Formulations of deacetylase inhibitors |
| 02/12/2009 | WO2008028963A3 Calreticulin for its use as a medication for the treatment of cancer in a mammal |
| 02/12/2009 | WO2008008539A3 Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor |
| 02/12/2009 | WO2008006187A3 Protein complexes for prevention and treatment of diseases with angiogenesis disorders |
| 02/12/2009 | WO2008004058A3 Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications |
| 02/12/2009 | WO2007146335A3 Compounds and compositions for treatment of cancer |
| 02/12/2009 | WO2007134169A3 Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof |
| 02/12/2009 | WO2007014743A8 Cd33-specific single-chain immunotoxin and method of use |
| 02/12/2009 | US20090043129 Potent and selective ligands of cannabinoid receptors |
| 02/12/2009 | US20090043091 Induce immunology response; anticancer agents; 6-(6-Morpholin-4-yl-4-oxo-4H-pyran-2-yl)-thianthrene-2-carboxylate sodium salt; 6-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-thianthrene-2-carboxylic acid methyl ester |
| 02/12/2009 | US20090042995 Therapeutic formulation |
| 02/12/2009 | US20090042992 Polymorphs of suberoylanilide hydroxamic acid |
| 02/12/2009 | US20090042966 anticarcinogenic agent; (2S)-3-[(5R)-1-Acetyl-3-(2,5-difluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-5-yl]-2-fluoropropan-1-amine for treating cancer |
| 02/12/2009 | US20090042965 Inhibitors for steroid response elements and related methods |
| 02/12/2009 | US20090042935 Novel iv formulation of tipifarnib |
| 02/12/2009 | US20090042929 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors |
| 02/12/2009 | US20090042924 1,6-dimethyl-3-(pyridin-4-yl)-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one, used as anticarcinogenic or antitumor agents |
| 02/12/2009 | US20090042923 Method of Treating Tumors with Azaxanthones |
| 02/12/2009 | US20090042922 Novel belactosin derivatives as therapeutic agents/biological probes and their synthesis |
| 02/12/2009 | US20090042920 Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
| 02/12/2009 | US20090042918 Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 |
| 02/12/2009 | US20090042914 Delayed release formulations of 6-mercaptopurine |
| 02/12/2009 | US20090042913 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor |
| 02/12/2009 | US20090042906 Methods for treating cancers associated with constitutive egfr signaling |
| 02/12/2009 | US20090042899 Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase |
| 02/12/2009 | US20090042894 Novel species of acrocarpospora, a method of preparing iodinin, and the uses of iodinin |
| 02/12/2009 | US20090042890 Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| 02/12/2009 | US20090042888 Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
| 02/12/2009 | US20090042885 2-(2-((2R)-2-heptylaminomethyl-5-oxopyrrolidin-1-yl)ethylthio)-1,3-thiazole-4-carboxylic acid; EP2 and/or EP4 receptor agonist; immune disease; antiallergens; alopecia; dysmenorrhea; erectile dysfuncction; antiarthritic agents; liver, respiratory, vascular, urogenital disorder |
| 02/12/2009 | US20090042884 kinase inhibitor; immunotherapy; viricides; function or behavior associated with PI3 kinase such as cancer, immune, cardiovascular, nervous system, metabolism/endocrine and neurological diseases, viral infection, inflammation; 6-(indol-4-yl)-4-(morpholin-4-yl)-2-[(2-(pyridin-2-yl)ethylamino]pyrimidine |
| 02/12/2009 | US20090042883 Antitumor agent |
| 02/12/2009 | US20090042882 Substituted acetamides as modulators of the ep2 receptor |
| 02/12/2009 | US20090042880 Novel 4-benzimidazol-2-ylpyridazin-3-one derivatives |
| 02/12/2009 | US20090042878 Thienopyrimidylamines as modulators of the ep2 receptor |
| 02/12/2009 | US20090042877 such as ethyl 6-oxo-7-phenyl-3-(pyridin-3-ylamino)-6,7-dihydrothieno [2,3-b]pyridine-2-carboxylate, potent and selective inhibitors of p38 MAP kinase and are of use in the prophylaxis and treatment of immune or inflammatory disorders |
| 02/12/2009 | US20090042872 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same |
| 02/12/2009 | US20090042866 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control |
| 02/12/2009 | US20090042865 Dna-pk inhibitors |
| 02/12/2009 | US20090042864 Pyrazole compounds |
| 02/12/2009 | US20090042845 Suppression and prevention of tumors |
| 02/12/2009 | US20090042844 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators |
| 02/12/2009 | US20090042838 Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin |
| 02/12/2009 | US20090042836 Proteasome inhibitors |
| 02/12/2009 | US20090042830 Novel oncogene, recombinant protein derived therefrom, and uses thereof |
| 02/12/2009 | US20090042820 Tubulin Binding Anti Cancer Agents And Prodrugs Thereof |
| 02/12/2009 | US20090042818 Liquiritigenin and Derivatives as Selective Estrogen Receptor Beta Agonists |
| 02/12/2009 | US20090042811 Synthesis of Glycerolipid Carbamates and Dicarbamates and Their Use as an Antitumor Compounds |
| 02/12/2009 | US20090042806 Transglutaminase inhibitors and methods of use thereof |
| 02/12/2009 | US20090042805 Peptides Useful As Dual Caspase-2/-6 Inhibitors And Their Biological Applications |
| 02/12/2009 | US20090042803 Inhibitors of protein kinases and uses thereof |
| 02/12/2009 | US20090042796 Derivatives of the il-2 receptor gamma chain, their production and use |
| 02/12/2009 | US20090042786 Kunitz-type recombinant inhibitor |
| 02/12/2009 | US20090042785 Compound with Affinity for the Cytotoxic T Lymphocyte-Associated Antigen (Ctla-4) |
| 02/12/2009 | US20090042782 Diagnostic and therapeutic strategies for conditions associated with the FLJ13639 gene |
| 02/12/2009 | US20090042778 Methods for Suppressing Neovascularization Using Ephrinb2 |
| 02/12/2009 | US20090042225 Method for selecting therapeutic agents for cancer treatment |
| 02/12/2009 | US20090042221 Preparing biopsy of tumorous tissue and monitoring chemosensitivity to anticarcinogenic agents; antitumor agents; drug screening |
| 02/12/2009 | US20090042199 Nucleotide sequences coding lymphocyte adhesion protein for use in treatment of autoimmunity, inflammation and infection |
| 02/12/2009 | US20090041876 Oil/fat-containing composition for suppression of carcinogenesis |
| 02/12/2009 | US20090041863 Use of GSK3 inhibitors in combination with radiation therapies |
| 02/12/2009 | US20090041853 Therapeutic bio platinum complex |
| 02/12/2009 | US20090041837 Aptamers utilized as targeting agents for pharmaceutical compounds used in the treatment of cancer and other diseases |
| 02/12/2009 | US20090041834 Compositions and methods for treating lymphoma |
| 02/12/2009 | US20090041797 Modified toxins |
| 02/12/2009 | US20090041793 Immunostimulatory Compositions and Uses Thereof |
| 02/12/2009 | US20090041788 Apo-2L receptor agonist and CPT-11 synergism |
| 02/12/2009 | US20090041767 Alpha 5 beta 1 integrin antagonist such as volociximab and a tyrosine kinase inhibitor such as sunitinib, sorafenib or bevacizumab; cancer |
| 02/12/2009 | US20090041758 Modified binding molecules comprising connecting peptides |
| 02/12/2009 | US20090041757 Bone morphogenetic protein antagonist and uses thereof |
| 02/12/2009 | US20090041756 121p1f1: a tissue specific protein highly expressed in various cancers |
| 02/12/2009 | US20090041755 Methods and Compositions For PDGF-D Activation and Inhibition |
| 02/12/2009 | US20090041749 Compositions and methods for the diagnosis and treatment of tumor |
| 02/12/2009 | US20090041740 Cancer treatment by metabolic modulations |
| 02/12/2009 | US20090041735 CD34 Stem cell-related methods and compositions |
| 02/12/2009 | US20090041726 Tumor therapy with high affinity laminin receptor-target vectors and combinations with chemotherapeutic agents |
| 02/12/2009 | US20090041660 new monoclonal antibodies and binding fragments which recognize and immunoreact with cell surface antigens found on small cell lung cancer (SCLC) cells; antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of SCLC disease |
| 02/12/2009 | DE102006047231B4 Substituierte Indeno[1,2-b]indolderivate als neue Hemmstoffe der Protein Kinase CK2 und ihre Verwendung als Tumor Therapeutika, Cytostatika und Diagnostika Substituted indeno [1,2-b] indole derivatives as new inhibitors of protein kinase CK2 and their use as antitumor agents, cytostatic agents and diagnostic agents |
| 02/12/2009 | DE102004059357B4 Antikörper, welcher die Interaktion von humanem Thy-1 und dessen Liganden blockiert, sowie dessen Verwendung Antibody that blocks the interaction of human Thy-1 and its ligands, and its use |
| 02/12/2009 | CA2699461A1 Inhibitors of intracellular urokinase plasminogen activator and methods of use thereof |
| 02/12/2009 | CA2695991A1 Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor |
| 02/12/2009 | CA2695857A1 Kinase inhibitors, compositions comprising them, and methods of their use |
| 02/12/2009 | CA2695809A1 Plant bioreactor for the production of interleukin-24 cytokine |
| 02/12/2009 | CA2695514A1 Ultraconserved regions encoding ncrnas |
| 02/12/2009 | CA2695478A1 Composition and therapeutic anti-tumour vaccine |
| 02/12/2009 | CA2695406A1 Crystalline form of a dihydropteridione derivative |
| 02/12/2009 | CA2695082A1 Peptide boronic acid and boronic ester compounds as proteasome inhibitors |
| 02/12/2009 | CA2694751A1 Therapeutic use of anti-tweak receptor antibodies |
| 02/12/2009 | CA2694434A1 Treatment of prion protein related diseases |
| 02/12/2009 | CA2693464A1 Anti-cd37 antibodies |
| 02/12/2009 | CA2691529A1 Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |